NCT00949325 · OUTCOME

Duration of Response

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma · Source last updated 2019-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: up to 5 years

What was measured

Number of days until documentation of disease progression or date of death from other cause

Analysis population: Although the original protocol specified that "duration of response" would be an outcome measure that would be obtained, appropriate data were not collected, so this outcome measure cannot be evaluated or reported.

Groups in this outcome

Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

description

Number of days until documentation of disease progression or date of death from other cause

groups

id
OG000
title
Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2

population Description

Although the original protocol specified that "duration of response" would be an outcome measure that would be obtained, appropriate data were not collected, so this outcome measure cannot be evaluated or reported.

reporting Status

POSTED

time Frame

up to 5 years

title

Duration of Response

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice